Kinnate Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Kinnate Biopharma wird ein Gewinn- und Umsatzwachstum von 14.6% bzw. 69.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 33.6% pro Jahr wachsen soll.

Wichtige Informationen

14.6%

Wachstumsrate der Gewinne

33.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	69.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:KNTE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-69	-36	-23	2
12/31/2025	N/A	-53	-37	-37	3
12/31/2024	N/A	-59	-54	-54	4
12/31/2023	N/A	-113	-100	-100	N/A
9/30/2023	N/A	-127	-107	-106	N/A
6/30/2023	N/A	-127	-102	-102	N/A
3/31/2023	N/A	-122	-96	-96	N/A
12/31/2022	N/A	-116	-92	-89	N/A
9/30/2022	N/A	-111	-91	-88	N/A
6/30/2022	N/A	-105	-88	-85	N/A
3/31/2022	N/A	-99	-81	-79	N/A
12/31/2021	N/A	-90	-72	-71	N/A
9/30/2021	N/A	-77	-62	-62	N/A
6/30/2021	N/A	-63	-53	-53	N/A
3/31/2021	N/A	-49	-41	-41	N/A
12/31/2020	N/A	-36	-30	-30	N/A
9/30/2020	N/A	-26	-20	-20	N/A
12/31/2019	N/A	-10	-11	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KNTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KNTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KNTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KNTE wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: KNTE wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KNTE in 3 Jahren voraussichtlich hoch sein wird

Kinnate Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 21% to US$4.53

Price target decreased by 84% to US$3.75

Price target increased by 8.1% to US$25.86

Price target decreased by 16% to US$25.00

Price target decreased to US$31.88

Price target decreased to US$40.71

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Insufficient new directors

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Price target increased by 8.1% to US$25.86

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Price target decreased by 16% to US$25.00

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Price target decreased to US$31.88

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Price target decreased to US$40.71

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Price target decreased to US$43.43

Chief Medical Officer recently bought US$339k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

New 90-day low: US$29.70

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Kinnate Biopharma Inc. has completed an IPO in the amount of $240 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken